ResMed AirSense 11 AutoSet CPAP: FDA-Cleared Sleep Apnea Treatment with Connected Monitoring

Untreated obstructive sleep apnea shortens life expectancy by an estimated 8 to 18 years. For the 80% of sufferers who remain undiagnosed, the most dangerous thing about their sleep is that it feels normal.

Presented By Our Partners

Obstructive sleep apnea (OSA) is not a minor inconvenience. It is a medical condition in which the upper airway collapses repeatedly during sleep, causing breathing cessations that last 10 seconds or longer, occurring dozens or even hundreds of times per night. Each event triggers a micro-arousal, a burst of sympathetic nervous system activation that prevents the brain from completing normal sleep cycles. The cumulative effect is devastating: a 2005 landmark study published in the New England Journal of Medicine by Marin et al. followed 1,651 men for over a decade and found that untreated severe OSA was associated with a nearly three-fold increase in fatal and non-fatal cardiovascular events. A 2017 meta-analysis in the Journal of the American Heart Association by Yin et al. confirmed that disrupted sleep, the hallmark of untreated OSA, carries significant all-cause and cardiovascular mortality risk across populations of 5.1 million participants.

Continuous positive airway pressure (CPAP) therapy remains the gold standard treatment for moderate to severe OSA. The ResMed AirSense 11 AutoSet represents the current state of the art in CPAP technology: an FDA-cleared, auto-titrating device with cloud-connected monitoring, integrated humidification, and algorithms designed to maximize both efficacy and patient compliance.

What Is the ResMed AirSense 11 AutoSet?

The ResMed AirSense 11 AutoSet is an auto-adjusting positive airway pressure (APAP) device that delivers pressurized air through a mask to keep the upper airway open during sleep. Unlike fixed-pressure CPAP machines that deliver a constant pressure throughout the night, the AutoSet uses ResMed’s AutoSet algorithm to continuously monitor breathing patterns and automatically adjust pressure on a breath-by-breath basis. When the algorithm detects airway narrowing, flow limitation, or apnea events, it increases pressure to resolve the obstruction. When the airway is stable, it reduces pressure to the minimum effective level, improving comfort and reducing air swallowing (aerophagia).

The device connects to the myAir app via built-in cellular and WiFi connectivity, providing patients with nightly therapy scores, usage data, leak rates, and events-per-hour metrics. Clinicians can also access this data remotely through ResMed’s AirView clinical portal, enabling telehealth management and early intervention when therapy issues arise. The AirSense 11 features an integrated heated humidifier (HumidAir), a color touchscreen interface, and compatibility with ResMed’s full range of masks including nasal, nasal pillow, and full-face options.

ResMed, an Australian-American company founded in 1989, is one of the two dominant manufacturers in the global CPAP market (alongside Philips Respironics, whose DreamStation devices were subject to a major safety recall in 2021). The AirSense 11 launched in 2021 as the successor to the widely used AirSense 10 platform and has become the most prescribed CPAP device in most markets.

The Science Behind It: CPAP Therapy and Cardiovascular Protection

The physiological damage caused by untreated OSA operates through several interconnected pathways. Each apnea event causes intermittent hypoxemia (drops in blood oxygen saturation), hypercapnia (carbon dioxide buildup), intrathoracic pressure swings, and sympathetic nervous system activation. Over months and years, these repeated insults produce sustained hypertension, endothelial dysfunction, systemic inflammation, insulin resistance, and cardiac remodeling. The American Heart Association has classified OSA as an independent risk factor for cardiovascular disease, and the European Society of Cardiology recommends OSA screening in patients with treatment-resistant hypertension, atrial fibrillation, and heart failure.

CPAP therapy addresses these mechanisms directly by maintaining airway patency throughout the night, eliminating the oxygen desaturation events, sleep fragmentation, and sympathetic surges that drive the downstream damage. A 2014 meta-analysis published in JAMA by Fava et al. examined 32 randomized controlled trials with 4,516 participants and found that CPAP therapy reduced systolic blood pressure by an average of 2.58 mmHg and diastolic blood pressure by 2.01 mmHg in patients with OSA. While these reductions may appear modest, epidemiological data suggests that a sustained 2 mmHg reduction in population blood pressure reduces stroke mortality by 10% and ischemic heart disease mortality by 7%.

The compliance challenge is CPAP therapy’s Achilles heel. Research published in the journal Chest has consistently shown that approximately 30% to 50% of patients prescribed CPAP abandon therapy within the first year, most commonly due to mask discomfort, pressure intolerance, nasal congestion, or simply finding the device inconvenient. The clinical benefits of CPAP are dose-dependent: studies have established a minimum threshold of approximately 4 hours per night for cardiovascular benefit, with greater benefits observed at 6 or more hours. Technologies that improve comfort and reduce barriers to consistent use directly improve clinical outcomes.

The auto-titrating approach used by the AirSense 11 addresses pressure intolerance specifically. By delivering only the minimum pressure necessary at each moment rather than a fixed maximum pressure all night, auto-CPAP reduces the average pressure experienced by the patient, which reduces mask leak, aerophagia, and the sensation of “fighting” the machine that drives many patients to non-compliance.

That is the science. Here is how the ResMed AirSense 11 applies it.

What the ResMed AirSense 11 Does Well

The AutoSet algorithm is the AirSense 11’s core differentiator. ResMed has refined this algorithm through decades of clinical research and billions of nights of therapy data. The breath-by-breath pressure adjustment responds to flow limitation (partial airway narrowing) before a full apnea event occurs, which means the device often prevents obstructions rather than merely responding to them. This proactive approach is clinically superior to fixed-pressure CPAP for most patients.

The connected monitoring ecosystem (myAir app for patients, AirView portal for clinicians) transforms CPAP from a passive device into a managed therapy platform. Patients receive a nightly therapy score that gamifies compliance, with coaching tips that address common issues (mask fit, leak management, sleep position). Clinicians can monitor patient data remotely and intervene early when usage drops or therapy quality declines, which research has shown significantly improves long-term compliance rates.

The integrated HumidAir heated humidifier addresses one of the most common complaints about CPAP therapy: nasal dryness and congestion. The humidifier’s climate control feature uses a sensor in the air tubing to adjust humidity delivery based on ambient conditions, maintaining consistent moisture levels regardless of room temperature or humidity changes throughout the night.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The device’s quiet operation (measured at 26.6 dBA at the lowest pressure setting) represents a significant improvement over older CPAP generations. Noise was historically a compliance barrier not only for the patient but for bed partners, and the AirSense 11’s whisper-quiet motor reduces this concern substantially.

Pricing, Access, and Practical Realities

The ResMed AirSense 11 AutoSet retails for approximately $849 to $1,099 without insurance coverage, depending on the supplier and whether the humidifier and tubing are included. With insurance, most patients pay significantly less: moderate to severe OSA with a confirmed diagnosis qualifies for coverage under most major medical plans, with typical out-of-pocket costs ranging from $0 to $300 depending on deductible and plan structure.

A CPAP device requires a prescription following a formal sleep study (in-lab polysomnography or home sleep apnea test). It cannot be purchased over the counter. The diagnostic pathway typically involves a referral to a sleep medicine physician, a sleep study, and a follow-up appointment to discuss results and initiate therapy. This clinical pathway ensures that CPAP therapy is appropriately prescribed and that the pressure settings are titrated to the individual patient’s needs.

The AirSense 11 AutoSet is FDA 510(k) cleared for the treatment of obstructive sleep apnea in adults. This is a genuine regulatory clearance based on clinical evidence of safety and efficacy, not a general wellness classification. The device is HSA/FSA eligible when prescribed for diagnosed OSA. Ongoing costs include replacement masks (every 3 months, $30 to $100 depending on type), filters (monthly, $5 to $10), and tubing (every 6 months, $15 to $30), most of which are insurance-reimbursable.

The myAir app is free to use and requires no subscription. AirView clinical monitoring is a service provided to healthcare providers at no cost to patients. Cellular connectivity (for automatic data upload to the cloud without requiring WiFi) is built into the device at no additional charge.

Who the ResMed AirSense 11 Is Best For

The AirSense 11 AutoSet is specifically designed for adults diagnosed with moderate to severe obstructive sleep apnea (Apnea-Hypopnea Index of 15 or higher) or mild OSA with significant symptoms. It is the appropriate device for patients who have completed a sleep study and received a CPAP prescription from a sleep medicine physician. Patients who previously tried and abandoned CPAP therapy due to pressure discomfort may find the auto-titrating algorithm more tolerable than their prior fixed-pressure experience.

Patients who value data and coaching will appreciate the myAir app’s nightly feedback loop, which provides actionable guidance on improving mask fit, managing leaks, and optimizing sleep position. Clinicians who want remote monitoring capabilities for their patient panels will find the AirView integration essential for telehealth-based sleep medicine practice.

Those for whom the AirSense 11 is not appropriate include individuals who have not been diagnosed with OSA through a formal sleep study. CPAP therapy is a prescription medical treatment, not a wellness device. People with mild snoring without apnea events do not need CPAP and should explore behavioral interventions (weight management, sleep position training, alcohol avoidance) first. Patients with central sleep apnea (CSA) require adaptive servo-ventilation (ASV) therapy rather than standard auto-CPAP, and should be evaluated by a sleep medicine specialist for appropriate device selection.

How the ResMed AirSense 11 Compares

The primary competitor is the Philips Respironics DreamStation 2, which offers similar auto-CPAP functionality and connected monitoring. However, Philips Respironics’ reputation was significantly damaged by the 2021 recall of its DreamStation 1 devices due to degrading sound abatement foam that could release particles and gases into the airstream. The DreamStation 2 uses a different foam formulation not affected by the recall, but the reputational impact has shifted significant market share toward ResMed. The AirSense 11 is generally considered to have a more refined auto-algorithm and better app experience, though both devices are clinically effective.

Against consumer sleep trackers (Oura Ring, Apple Watch, Eight Sleep, Withings), the AirSense 11 occupies an entirely different category. Consumer trackers monitor sleep; the AirSense 11 treats a diagnosed medical condition. For patients with moderate to severe OSA, no consumer sleep tracker can substitute for CPAP therapy, though wearable trackers can provide complementary data about sleep quality on therapy. Some patients use an Oura Ring or Apple Watch alongside their CPAP to assess how effectively the therapy is improving their overall sleep architecture.

Lower-cost fixed-pressure CPAP devices (available for $400 to $600) can serve patients whose pressure requirements are stable and well-established. However, the auto-titrating capability of the AirSense 11 provides better comfort for most patients and accommodates night-to-night variability in airway collapsibility caused by factors like alcohol consumption, nasal congestion, sleep position, and weight fluctuation.

Limitations and Open Questions

CPAP therapy requires nightly compliance to deliver its benefits. The device must be worn for the duration of sleep, every night, indefinitely. Approximately 30% to 50% of patients struggle with long-term adherence despite improved comfort in modern devices. Mask fit issues, skin irritation, nasal congestion, claustrophobia, and the social impact of wearing a mask to bed remain real barriers for many patients.

The device requires regular maintenance: mask replacement every 1 to 3 months, filter replacement monthly, tubing replacement every 6 months, and water chamber cleaning weekly. While these tasks are straightforward, they add a maintenance burden that some patients find cumbersome.

CPAP therapy addresses the mechanical obstruction of the airway but does not cure the underlying condition. If the patient stops using CPAP, the apnea events resume immediately. Weight loss, positional therapy, oral appliances, and surgical options (such as hypoglossal nerve stimulation via the Inspire device) may offer alternatives or complementary treatments for selected patients.

The device’s reliance on cloud connectivity for full monitoring functionality raises data privacy considerations. Patient therapy data is stored on ResMed’s servers and shared with healthcare providers through AirView. Patients should understand the data-sharing practices associated with their device and discuss any concerns with their prescribing physician.

What This Means for Your Health

Among all the devices covered in Healthcare Discovery‘s healthtech intelligence reports, the ResMed AirSense 11 holds a unique position: it is the only FDA-cleared medical treatment device, not a wellness tracker. For patients with diagnosed obstructive sleep apnea, this device does not merely monitor a health metric; it actively treats a condition that, left untreated, significantly accelerates the progression of The Four Villains: cardiovascular disease, cancer, neurodegenerative disease, and metabolic dysfunction.

Sleep apnea is a direct threat to the longevity framework. Every night of untreated OSA delivers hundreds of oxygen desaturation events, cortisol surges, and sleep architecture disruptions that compound into measurable organ damage over years and decades. CPAP therapy, when used consistently, reverses much of this damage: blood pressure drops, insulin sensitivity improves, inflammatory markers decline, and sleep architecture normalizes. The magnitude of benefit is proportional to the severity of the condition and the consistency of therapy use.

If you snore heavily, wake unrefreshed despite adequate sleep duration, experience daytime sleepiness, or have been told by a bed partner that you stop breathing during sleep, a formal sleep evaluation is one of the highest-yield health actions you can take. The path from evaluation to diagnosis to effective CPAP therapy may add years to your life and significantly improve the quality of every waking hour. Among the Five Pillars, sleep is the foundation, and for the estimated 80% of sleep apnea sufferers who remain undiagnosed, addressing this condition may be the single most impactful health decision they will ever make.

Frequently Asked Questions

Do I need a prescription for the ResMed AirSense 11?
Yes. The ResMed AirSense 11 AutoSet is an FDA-cleared medical device that requires a prescription from a licensed physician, typically a sleep medicine specialist. A prescription follows a formal diagnosis of obstructive sleep apnea through either in-lab polysomnography or a home sleep apnea test (HSAT). The device cannot be legally purchased without a prescription. Your primary care physician can refer you for a sleep study if OSA is suspected.

How much does the ResMed AirSense 11 cost with and without insurance?
Without insurance, the AirSense 11 AutoSet costs approximately $849 to $1,099 depending on the supplier and accessories included. With insurance coverage for diagnosed OSA, most patients pay $0 to $300 out of pocket, as moderate to severe sleep apnea qualifies for coverage under most major medical plans. Ongoing supply costs (masks, filters, tubing) total approximately $200 to $400 per year and are typically insurance-reimbursable. The device is HSA/FSA eligible.

How does the ResMed AirSense 11 AutoSet differ from a fixed-pressure CPAP?
The AirSense 11 AutoSet uses ResMed’s auto-titrating algorithm to adjust air pressure breath by breath based on real-time breathing patterns. Fixed-pressure CPAP delivers a constant pressure all night. The AutoSet approach provides higher pressure only when needed (during airway narrowing or apnea events) and reduces pressure when the airway is stable, resulting in a lower average pressure that improves comfort and reduces side effects like aerophagia and mask leak. Most patients prefer auto-CPAP over fixed-pressure therapy.

What is the myAir app and does it cost anything?
myAir is ResMed’s free companion app for AirSense 11 users. It provides a nightly therapy score (0 to 100) based on usage hours, mask seal quality, events per hour, and mask on/off events. The app offers personalized coaching tips and tracks therapy trends over time. There is no subscription fee. The AirSense 11 uploads data automatically via built-in cellular connectivity, so a WiFi connection is helpful but not strictly required. Clinicians can access the same data through ResMed’s AirView portal.

Is the ResMed AirSense 11 quiet enough for a bed partner?
The AirSense 11 produces approximately 26.6 dBA at the lowest pressure setting, which is quieter than a whisper (30 dBA) and significantly quieter than the snoring it replaces (60 to 90 dBA for moderate to severe snoring). Most bed partners report that the device is substantially less disruptive than the untreated snoring and breathing cessations that preceded CPAP therapy. Mask selection also affects noise; nasal pillow masks are generally the quietest option.

How long do I have to use CPAP therapy?
CPAP therapy is an ongoing treatment, not a cure. If you stop using the device, obstructive sleep apnea events resume immediately because the underlying airway anatomy has not changed. Most patients use CPAP indefinitely, though weight loss (particularly 10% or more of body weight) can reduce OSA severity in some patients enough to reduce or eliminate the need for therapy. Alternative treatments including oral appliances and hypoglossal nerve stimulation (Inspire device) may be appropriate for selected patients. Discuss long-term treatment planning with your sleep medicine physician.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.